Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 331

Similar articles for PubMed (Select 18440920)

1.

Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir.

Klein CE, Chiu YL, Cai Y, Beck K, King KR, Causemaker SJ, Doan T, Esslinger HU, Podsadecki TJ, Hanna GJ.

J Clin Pharmacol. 2008 May;48(5):553-62. doi: 10.1177/0091270007313392.

PMID:
18440920
2.

Pharmacokinetic Interactions between BMS-626529, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug BMS-663068, and Ritonavir or Ritonavir-Boosted Atazanavir in Healthy Subjects.

Zhu L, Hruska M, Hwang C, Shah V, Furlong M, Hanna GJ, Bertz R, Savant Landry I.

Antimicrob Agents Chemother. 2015 Jul;59(7):3816-22. doi: 10.1128/AAC.04914-14. Epub 2015 Apr 13.

PMID:
25870057
3.

Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine.

Kletzl H, Giraudon M, Ducray PS, Abt M, Hamilton M, Lum BL.

Anticancer Drugs. 2015 Jun;26(5):565-72. doi: 10.1097/CAD.0000000000000212.

PMID:
25643050
4.

Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors?

Hill A, Khoo S, Back D, Pozniak A, Boffito M.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19583. doi: 10.7448/IAS.17.4.19583. eCollection 2014.

5.

Voriconazole and atazanavir: a CYP2C19-dependent manageable drug-drug interaction.

Calcagno A, Baietto L, Pagani N, Simiele M, Audagnotto S, D'Avolio A, De Rosa FG, Di Perri G, Bonora S.

Pharmacogenomics. 2014 Jul;15(10):1281-6. doi: 10.2217/pgs.14.92.

PMID:
25155930
6.

Pharmacokinetic evaluations of the co-administrations of vandetanib and metformin, digoxin, midazolam, omeprazole or ranitidine.

Johansson S, Read J, Oliver S, Steinberg M, Li Y, Lisbon E, Mathews D, Leese PT, Martin P.

Clin Pharmacokinet. 2014 Sep;53(9):837-47. doi: 10.1007/s40262-014-0161-2. Erratum in: Clin Pharmacokinet. 2014 Nov;53(11):1063.

PMID:
25117183
7.

Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms.

D'Avolio A, Carcieri C, Cusato J, Simiele M, Calcagno A, Allegra S, Sciandra M, Trentini L, Di Perri G, Bonora S.

J Antimicrob Chemother. 2014 Nov;69(11):3061-6. doi: 10.1093/jac/dku234. Epub 2014 Jul 4.

PMID:
24997317
8.

In Vitro and In Situ evaluation of pH-dependence of atazanavir intestinal permeability and interactions with acid-reducing agents.

Kis O, Walmsley SL, Bendayan R.

Pharm Res. 2014 Sep;31(9):2404-19. doi: 10.1007/s11095-014-1336-0. Epub 2014 Mar 5.

PMID:
24595498
9.

Role of P-glycoprotein in the distribution of the HIV protease inhibitor atazanavir in the brain and male genital tract.

Robillard KR, Chan GN, Zhang G, la Porte C, Cameron W, Bendayan R.

Antimicrob Agents Chemother. 2014;58(3):1713-22. doi: 10.1128/AAC.02031-13. Epub 2013 Dec 30.

10.

Safety and pharmacokinetics of the HIV-1 protease inhibitor TMC310911 coadministered with ritonavir in healthy participants: results from 2 phase 1 studies.

Hoetelmans RM, Dierynck I, Smyej I, Meyvisch P, Jacquemyn B, Marien K, Simmen K, Verloes R.

J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):299-305. doi: 10.1097/QAI.0000000000000011.

PMID:
24121757
11.

Effect of meal and antisecretory agents on the pharmacokinetics of danoprevir/ritonavir in healthy volunteers.

Morcos PN, Moreira SA, Navarro MT, Bech N, Quatkemeyer A, Smith PF, Brennan BJ.

J Pharm Pharmacol. 2014 Jan;66(1):23-31. doi: 10.1111/jphp.12151. Epub 2013 Oct 10.

PMID:
24117531
12.

Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects.

Vourvahis M, Plotka A, Mendes da Costa L, Fang A, Heera J.

Antimicrob Agents Chemother. 2013 Dec;57(12):6158-64. doi: 10.1128/AAC.01098-13. Epub 2013 Sep 30.

13.

Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.

Bifano M, Hwang C, Oosterhuis B, Hartstra J, Grasela D, Tiessen R, Velinova-Donga M, Kandoussi H, Sevinsky H, Bertz R.

Antivir Ther. 2013;18(7):931-40. doi: 10.3851/IMP2674. Epub 2013 Aug 20.

PMID:
23963204
14.

Pharmacokinetics of once-daily boosted elvitegravir when administered in combination with acid-reducing agents.

Ramanathan S, Mathias A, Wei X, Shen G, Koziara J, Cheng A, Kearney BP.

J Acquir Immune Defic Syndr. 2013 Sep 1;64(1):45-50. doi: 10.1097/QAI.0b013e31829ecd3b.

PMID:
23774876
15.

Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients.

Ma Q, Gelbard HA, Maggirwar SB, Dewhurst S, Gendelman HE, Peterson DR, DiFrancesco R, Hochreiter JS, Morse GD, Schifitto G.

J Neurovirol. 2013 Jun;19(3):254-60. doi: 10.1007/s13365-013-0172-z. Epub 2013 Jun 5.

16.

Coadministration of atazanavir-ritonavir and zinc sulfate: impact on hyperbilirubinemia and pharmacokinetics.

Moyle G, Else L, Jackson A, Back D, Yapa MH, Seymour N, Ringner-Nackter L, Karolia Z, Gazzard B, Boffito M.

Antimicrob Agents Chemother. 2013 Aug;57(8):3640-4. doi: 10.1128/AAC.00357-13. Epub 2013 May 20.

17.

A maintenance dose of atazanavir/ritonavir 200/100 mg once daily is effective in virologically suppressed HIV-1-infected patients.

Lanzafame M, Lattuada E, Rigo F, Vento S.

J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):e81-2. doi: 10.1097/QAI.0b013e3182928f10. No abstract available.

PMID:
23666142
18.

Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy.

Gautam N, Roy U, Balkundi S, Puligujja P, Guo D, Smith N, Liu XM, Lamberty B, Morsey B, Fox HS, McMillan J, Gendelman HE, Alnouti Y.

Antimicrob Agents Chemother. 2013 Jul;57(7):3110-20. doi: 10.1128/AAC.00267-13. Epub 2013 Apr 22.

19.

Co-administration of a commonly used Zimbabwean herbal treatment (African potato) does not alter the pharmacokinetics of lopinavir/ritonavir.

Gwaza L, Aweeka F, Greenblatt R, Lizak P, Huang L, Guglielmo BJ.

Int J Infect Dis. 2013 Oct;17(10):e857-61. doi: 10.1016/j.ijid.2013.02.017. Epub 2013 Apr 12.

20.

Optimized administration regimen of lopinavir for a myocardial ischaemia reperfusion study in Sprague-Dawley rats.

Katayama M, Jiamsripong P, Bukatina AE, Lombari TR, McMahon EM, Gades NM, Belohlavek M.

Lab Anim. 2013 Apr;47(2):122-6. doi: 10.1177/0023677213476864.

PMID:
23563365
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk